References
- Tunstall-PedoeH, ChenR, KramarzP. Prevalence of individuals with both raised blood pressure and raised cholesterol in WHO MONICA project population surveys 1989–97. Pharmacoepidemiol Drug Saf. 2004;13(Suppl 1):S307–S308.
- EganBM, LiJ, QanungoS, WolfmanTE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988–2010. Circulation. 2013;128(1):29–41. doi:10.1161/CIRCULATIONAHA.112.00050023817481
- IvanovicB, TadicM. Hypercholesterolemia and hypertension: two sides of the same coin. Am J Cardiovasc Drugs. 2015;15(6):403–414. doi:10.1007/s40256-015-0128-126062915
- WheltonPK, CareyRM, AronowWS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.00629146535
- DahlöfB. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol. 2010;105(1):3A–9A. doi:10.1016/j.amjcard.2009.10.007
- NickenigG. Should angiotensin II receptor blockers and statins be combined? Circulation. 2004;110:1013–1020. doi:10.1161/01.CIR.0000139857.85424.4515326080
- YiS, KimT-E, YoonSH, et al. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol. 2011;57(6):682–689. doi:10.1097/FJC.0b013e31821795d021394036
- LennernäsH. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42(13):1141–1160. doi:10.2165/00003088-200342130-0000514531725
- GhimJ-L, PaikSH, HasanuzzamanM, et al. Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects. J Clin Pharmacol. 2016;56(5):576–580. doi:10.1002/jcph.61826272450
- ParkJ, KimCO, JinBH, et al. Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers. Transl Clin Pharmacol. 2017;25(4):202–208. doi:10.12793/tcp.2017.25.4.20232095476
- DavitBM, ConnerDP, Fabian-FritschB, et al. Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications. AAPS J. 2008;10(1):148–156. doi:10.1208/s12248-008-9015-x18446515
- ChoiY, LeeS, JangI-J, et al. Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers. Drug Des Devel Ther. 2018;12:2301. doi:10.2147/DDDT.S165171
- SternRH, Yang-B-B, HounslowNJ, et al. Pharmacodynamics and pharmacokinetic‐pharmacodynamic relationships of atorvastatin, an HMG‐CoA reductase inhibitor. J Clin Pharmacol. 2000;40(6):616–623. doi:10.1002/j.1552-4604.2000.tb05987.x10868312
- Committee for Medicinal Products for Human Use. Guideline on the Investigation of Bioequivalence. London: European Medicines Agency; 2010.
- Food and Drug Administration. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Washington, DC: FDA; 2001.
- HyslopT, IglewiczB. Alternative cross-over designs for individual bioequivalence. Poster presented at: Annual Meeting of the American statistical association; 2001.
- JeonH, LimKS, ShinK-H, et al. Assessment of the drug–drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers. J Cardiovasc Pharmacol. 2012;59(1):84–91. doi:10.1097/FJC.0b013e318237389e21934629
- ShinK-H, KimT-E, KimSE, et al. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol. 2011;58(5):492–499. doi:10.1097/FJC.0b013e31822b909221765368
- WhitfieldLR, PorcariAR, AlveyC, et al. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol. 2011;51(3):378–388. doi:10.1177/009127001036644620413454